je.st
news
Tag: of
Over 20 million affected by El Nio, urgent action needed to reduce impact of disasters
2015-10-02 13:17:00| Climate Ark Climate Change & Global Warming Newsfeed
Blue and Green: In a year of unprecedented humanitarian need, El Nio is putting tens of millions of people at risk of drought and floods. CARE is scaling up life-saving assistance and urges governments to act now to reduce the impact of the disasters to come. The ongoing crises in Syria, Yemen and elsewhere have caused displacement and humanitarian needs on a scale never before recorded. Yet it is about to get worse. A global weather phenomenon known as El Nio is on its way, and its impact is predicted to...
Tags: of
action
needed
million
M&H Packages a New Range of Shampoos for ASDA
2015-10-02 12:31:11| Industrial Newsroom - All News for Today
MH Plastics has recently packaged ASDAs new range of own brand shampoos on behalf of Potter Moore. Using the stylish PET Contour bottle (4145) with an oval flip-top (8337) in PP the new family comprises a range of shampoo bottles and conditioner tottles. A bright, vibrant colour scheme was used to reflect the...
Rohde & Schwarz, Vector And Commsignia Demonstrate The First End-To-End Tester For V2X Applications Of Tomorrow
2015-10-02 07:13:54| rfglobalnet Home Page
Future intelligent transport systems (ITS) will be implemented using standards such as IEEE 802.11p WLAN. IEEE 802.11p enables vehicles and infrastructures to share information in order to warn drivers of hazards such as accidents, construction zones and slippery roads.
Tags: of
applications
demonstrate
tomorrow
Loophole in 1970 Clean Air Act may prevent criminal prosecution of VW
2015-10-01 19:01:31| Extremetech
The EPA may not have the ability to bring criminal charges against VW, thanks to a loophole in the 1970 Clean Air Act.
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-10-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [521] [522] [523] [524] [525] [526] [527] [528] [529] [530] [531] [532] [533] [534] [535] [536] [537] [538] [539] [540] next »